

## Division of AIDS ClinicalTrials.gov Protocol Checklist

This form is intended to be filled out electronically. This form will identify which conditions must be met to fulfill requirements set forth by the Food and Drug Administration Amendments Act of 2007 (FDAAA) and the NIH Policy on Dissemination of NIH-funded Clinical Trial Information. This form should be submitted along with to-be Version 1.0 main protocol documents at the time of Full Regulatory Review.

Contact Email	Protocol Number	Today's Date
Contact Name	DAIDS-ES ID (if known)	
<b>Contact Role:</b>		
<input type="checkbox"/> Central Contact	<input type="checkbox"/> Principal Investigator	<input type="checkbox"/> Sponsor
<input type="checkbox"/> Sponsor-Investigator	<input type="checkbox"/> Results point of contact	

Please answer all 6 questions to determine whether reporting to ClinicalTrials.gov is required.

### FDAAA Applicable Clinical Trial (ACT) Determination\* (Questions 1-4)

Questions	Yes	No
1. Is the study interventional (a clinical trial) per FDAAA?	<input type="checkbox"/>	<input type="checkbox"/>
2. Do ANY of the following apply (is the answer "Yes" to at least one of the following sub-questions: 2a, 2b, OR 2c)?		
a. Is at least one study facility located in the United States or a U.S. territory?		
b. Is the study conducted under a United States Food and Drug Administration (U.S. FDA) Investigational New Drug application (IND) or Investigational Device Exemption (IDE)?	<input type="checkbox"/>	<input type="checkbox"/>
c. Does the study involve a drug, biological, or device product that is manufactured in and exported from the U.S. (or a U.S. territory) for study in another country?		
3. Does the study evaluate at least one drug, biological, or device product that is regulated by the U.S. FDA?	<input type="checkbox"/>	<input type="checkbox"/>
4. Is the study:		
(a) higher than a Phase 1 trial of a drug and/or biological product, or	<input type="checkbox"/>	<input type="checkbox"/>
(b) a device study other than a device feasibility study?		

If "Yes" is selected for questions 1-4 and the study was initiated on or after January 18, 2017, the trial meets the definition of an ACT that is required to be registered under 42 CFR 11.22. See [https://prsinfo.clinicaltrials.gov/ACT\\_Checklist.pdf](https://prsinfo.clinicaltrials.gov/ACT_Checklist.pdf) for additional information.

### NIH Policy on the Dissemination of NIH-Funded Clinical Trials Information\*\* (Questions 5-6)

Questions	Yes	No
5. Is the study a clinical trial per the NIH policy? For help in determining, please see the NIH Grants Decision Tool found at <a href="https://grants.nih.gov/ct-decision/index.htm">https://grants.nih.gov/ct-decision/index.htm</a> .	<input type="checkbox"/>	<input type="checkbox"/>
6. Is the clinical trial funded in whole or in part by the NIH? Note: NIH Policy does not apply to a clinical trial that uses NIH-supported infrastructure but does not receive NIH funds to support its conduct. See <a href="https://grants.nih.gov/grants/guide/notice-files/not-od-16-149.html">https://grants.nih.gov/grants/guide/notice-files/not-od-16-149.html</a> for additional information.	<input type="checkbox"/>	<input type="checkbox"/>

### Sub-Study Results Submission:

None:       Separate:       Part of a parent study:

## Division of AIDS ClinicalTrials.gov Protocol Checklist Continued

### ClinicalTrials.gov Results Reporting Required

If “Yes” is selected for questions 1-4, the clinical trial information must be posted on ClinicalTrials.gov. Please complete the box below.

If “Yes” is selected for questions 5 and 6 (even if one of the questions in 1-4 is “No”), the clinical trial information must be posted on ClinicalTrials.gov. Please complete the box below.

For voluntary basic results reporting not subject to FDAAA regulations or the NIH Policy on the Dissemination of NIH-Funded Clinical Trials Information requirements, please complete the box below.

Clinical Trials determined to be applicable per FDAAA requirements or required per NIH Policy on the Dissemination of NIH-Funded Clinical Trials Information must be registered to ClinicalTrials.gov, must post basic results, and must include mandatory language in the informed consent form regarding ClinicalTrials.gov.

Please include the below information:

Sponsor: DAIDS  OR Other:

Anticipated Primary Completion Date (APCD):

The APCD is a projected date and allowed to be updated as the study progresses. Updates should be sent to [CSIO@tech-res.com](mailto:CSIO@tech-res.com).

---

Note: For DAIDS-held IND studies, the responsibility to meet the requirements falls within DAIDS (“Responsible Party”). For other studies (e.g., Network Non-IND, non-DAIDS held IND, non-network non-IND, etc.), the responsibility generally lies with the grantee institution, organization, and/or IND holder.

\*For the complete statutory definitions and more detailed information on NIH's current thinking on FDAAA, please visit: <http://prsinfo.clinicaltrials.gov/>.

\*\*For information about the NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information, please visit: <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-149.html>. Policy effective for competing applications and contract proposals submitted on or after January 18, 2017 (<https://grants.nih.gov/policy/clinical-trials/reporting/understanding.htm>).

Please note this checklist does not address International Committee of Medical Journal Editors (ICMJE) requirements. For information on ICMJE requirements, please visit: <http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/>.

For questions regarding this form, please contact [CSIO@tech-res.com](mailto:CSIO@tech-res.com).